Cargando…
A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
Autores principales: | Peng, Wei, Li, Si, Li, Lijian, Xiao, Mingzhe, Zhong, Jincai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474378/ https://www.ncbi.nlm.nih.gov/pubmed/34589975 http://dx.doi.org/10.1016/j.jtocrr.2020.100112 |
Ejemplares similares
-
Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
por: Yan, Lingxin, et al.
Publicado: (2023) -
Anti-cancer effect of LINC00478 in bladder cancer correlates with KDM1A-dependent MMP9 demethylation
por: Yang, Han-Jie, et al.
Publicado: (2022) -
A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
por: Wang, Ting, et al.
Publicado: (2023) -
Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
por: Lin, Jieheng, et al.
Publicado: (2022) -
Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)